Due to Pfizer’s underperformance relative to the healthcare sector over the past year, Wall Street analysts remain cautious ...

New products are already generating growth.

Johnson & Johnson is upgraded to Buy and Pfizer to Hold reflecting improved profitability outlooks post-Q4 2025 earnings.

Richard Saperstein, Chief Investment Officer at Treasury Partner, joins CNBC's Halftime Report to detail his latest portfolio ...

Pfizer says it is standing behind its dividend, which makes the stock's 6.4% yield quite attractive.

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Pfizer Inc. (NYSE:PFE) is among the Best Affordable Stocks Under $40 to Buy. On February 17, Pfizer Inc. (NYSE:PFE) announced ...

Fintel reports that on February 20, 2026, Barclays initiated coverage of Pfizer (NYSE:PFE) with a Underweight recommendation. Analyst Price Forecast Suggests 9.96% Upside As of February 4, 2026, the ...

As of Wednesday, February 25, Sangamo Therapeutics, Inc.’s SGMO share price has surged by 14.48%, which has investors questioning if this is right time to sell.

As Chair of the Scientific Advisory Committee, Dr. Lewis-Hall will provide leadership in scientific, clinical, and regulatory governance across Helus' portfolio, advising on discovery opportunities, ...

Learn more about whether IDEAYA Biosciences, Inc. or Travere Therapeutics, Inc. is a better investment based on AAII's A+ ...